Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Greenwich LifeSciences (GLSI) Profit After Tax (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Profit After Tax readings, the most recent being -$4.2 million for Q3 2025.

  • Quarterly Profit After Tax fell 55.57% to -$4.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$19.5 million through Sep 2025, down 85.57% year-over-year, with the annual reading at -$15.8 million for FY2024, 77.57% down from the prior year.
  • Profit After Tax hit -$4.2 million in Q3 2025 for Greenwich LifeSciences, down from -$4.0 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$597008.0 in Q1 2021 and bottomed at -$8.0 million in Q4 2024.
  • Average Profit After Tax over 5 years is -$2.6 million, with a median of -$2.4 million recorded in 2023.
  • The largest annual shift saw Profit After Tax plummeted 256.29% in 2021 before it rose 1.57% in 2023.
  • Greenwich LifeSciences' Profit After Tax stood at -$2.4 million in 2021, then decreased by 18.21% to -$2.8 million in 2022, then increased by 1.57% to -$2.7 million in 2023, then plummeted by 192.72% to -$8.0 million in 2024, then skyrocketed by 48.36% to -$4.2 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Profit After Tax are -$4.2 million (Q3 2025), -$4.0 million (Q2 2025), and -$3.3 million (Q1 2025).